Collectively, these results indicate that low expression of PCK1 mainly reduces H3K9me3 modification by restricting SAM generation, which enhances S100A11 transcription and expression and aberrant activation of the PI3K/AKT pathway, subsequently promoting HCC malignant development and progression. The gene discussed is PCK1; the disease is hepatocellular carcinoma.